{
    "clinical_study": {
        "@rank": "89004", 
        "arm_group": [
            {
                "arm_group_label": "NVN1000 1% Gel", 
                "arm_group_type": "Experimental", 
                "description": "NVN1000 1% Gel twice daily"
            }, 
            {
                "arm_group_label": "NVN1000 4% Gel", 
                "arm_group_type": "Experimental", 
                "description": "NVN1000 4% Gel twice daily"
            }, 
            {
                "arm_group_label": "Vehicle Gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle Gel twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 12 week clinical trial in subjects with acne vulgaris.  Subjects will be\n      randomized to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel twice daily.  Safety,\n      tolerability and efficacy will be assessed over the course of the study."
        }, 
        "brief_title": "A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, evaluator and subject blinded, randomized, vehicle-controlled,\n      parallel group, dose-ranging study to be conducted in approximately 150 subjects with acne\n      vulgaris. Subjects who satisfy the entry criteria at the Baseline visit will be randomized\n      to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel in a 1:1:1 ratio.   Efficacy assessments\n      will include inflammatory and non-inflammatory lesion counts and investigator global\n      assessments (IGA).  Tolerability and safety assessments include cutaneous tolerability\n      evaluation, adverse event collection, physical exams, and laboratory studies. Subjects will\n      return for post-baseline evaluation at Weeks 2, 4, 8, and 12."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with acne vulgaris and at least 20 but no more than 40 inflammatory lesions,\n             25-70 non-inflammatory lesions, no more than 2 nodules on the face\n\n          -  Baseline IGA score of mild, moderate or severe\n\n          -  Women of child-bearing potential must agree to use an effective method of birth\n             control during the study and for 30 days after their final study visit\n\n        Exclusion Criteria:\n\n          -  Any dermatologic condition or other medical problem that could interfere with\n             clinical evaluation or requires the use of topical or systemic therapy that make\n             evaluations and lesion count inconclusive\n\n          -  Female subjects who are pregnant, nursing, or considering becoming pregnant\n\n          -  Methemoglobin > 2% at baseline\n\n          -  Clinically significant anemia at baseline\n\n          -  Use of topical or systemic medications to treat acne\n\n          -  Use of medications that make acne worse, associated with methemoglobinemia, or nitric\n             oxide donors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "153", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844752", 
            "org_study_id": "NI-AC201"
        }, 
        "intervention": [
            {
                "arm_group_label": "NVN1000 1% Gel", 
                "description": "Twice daily NVN1000 1% Gel for 12 weeks", 
                "intervention_name": "NVN1000 1% Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NVN1000 4% Gel", 
                "description": "Twice daily NVN1000 4% Gel for 12 weeks", 
                "intervention_name": "NVN1000 4% Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle Gel", 
                "description": "Twice daily Vehicle Gel for 12 weeks", 
                "intervention_name": "Vehicle Gel", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "acne", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santo Domingo", 
                        "country": "Dominican Republic"
                    }, 
                    "name": "Instituto Dermatologico & Cirugia de Piel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Pedro Sula", 
                        "country": "Honduras"
                    }, 
                    "name": "Hospital Y Clinica Bendana"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Panama City", 
                        "country": "Panama"
                    }, 
                    "name": "Hosptal Punta Pacifica"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Dominican Republic", 
                "Honduras", 
                "Panama"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled, Parallel Group, 3-arm Study Comparing the Efficacy, Tolerability and Safety of 2 Concentrations of NVN1000 Gel and Vehicle Gel Twice Daily in the Treatment of Acne Vulgaris.", 
        "overall_official": {
            "affiliation": "Novan, Inc.", 
            "last_name": "Joyce Rico, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Honduras: Investigation Committee of Biomedical Ethics", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The absolute change from baseline in non-inflammatory lesion counts at Week 12", 
            "measure": "The absolute change from baseline in non-inflammatory lesion counts at Week 12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844752"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The absolute change from baseline in inflammatory lesion counts at Week 12", 
                "measure": "The absolute change from baseline in inflammatory lesion counts at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Analysis of the dichotomized IGA scores (success vs failure) at Week 12. \"Success\" is defined as a score of \"clear\" or \"almost clear\" and a 2 point improvement in the IGA score from Baseline.", 
                "measure": "Success on the Investigator Global Assessment (IGA) at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 week"
            }
        ], 
        "source": "Novan, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novan, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}